Komori

Briefing Materials for the Second-Quarter Financial Results for the Fiscal Year Ending March 2027

Results presentationFirst half, FY ending Mar 2027Published 2026-11-17 09:00

In the first half of the fiscal year ending March 2027, revenue fell below the prior-year period and the operating loss widened. Selling, general and administrative expenses increased, mainly due to costs related to the transfer of production, while subsidy income meant that the deterioration in the ordinary loss and interim net loss was smaller than that in the operating loss.

In short

Forecast unchanged
  • First-half revenue was ¥175 million, down 12.5% year on year.
  • The operating loss widened to ¥498 million due to costs related to the transfer of production, among other factors.
  • The company outlined a policy of building a foundation for medium- to long-term growth through approval for recurrent meningioma and expansion into mainland China.

What they reported

this period against the same period a year earlier, and where they now expect the year to end

Sales

¥0.2bn−12.5%vs a year earlier
H1 FY26¥0.2bnH1 FY27¥0.2bn
FY25FY26FY27 · this year0011¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4±0%−23%this yearvs same quarter last yearnew forecast0.4 a quarterold forecast0.4 a quarterlast year
Sales by quarter
Period¥bn
FY25 Q10.1
FY25 Q20.1
FY25 Q30.1
FY25 Q40.7
FY26 Q10.1
FY26 Q20.1
FY26 Q30.1
FY26 Q40.1
FY27 Q10.1
FY27 Q20.1
last year 0.3
was 1.0
now 1.0
Full-year forecast, ¥bn±0.0% vs the old forecast
Old and new forecast from the company's results releases
Why

First-half revenue declined 12.5% year on year.

当上期の売上高は、前年同期比12.5%減の175百万円となりました。
Revenue for the first half was ¥175 million, down 12.5% year on year.

Operating profit

−¥498.0mloss widenedvs a year earlier
H1 FY26−¥298.0mH1 FY27−¥498.0m
FY25FY26FY27 · this year-2000200¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼this yearvs same quarter last yearnew forecast-99.0 a quarterold forecast-99.0 a quarterlast year
Operating profit by quarter
Period¥m
FY25 Q1-166.0
FY25 Q2-103.0
FY25 Q3-106.0
FY25 Q4285.0
FY26 Q1-151.0
FY26 Q2-147.0
FY26 Q3-214.0
FY26 Q4-236.0
FY27 Q1-245.0
FY27 Q2-253.0
last year -748.0
was -696.0
now -696.0
Full-year forecast, ¥m±0.0% vs the old forecast
Old and new forecast from the company's results releases
Why

Although the gross profit margin was at the same level as in the prior-year period, the operating loss widened as outsourcing expenses related to the transfer of production increased.

売上総利益率は前年同期と同水準を維持したものの、生産移管に関連する業務委託費の増加等により、営業利益は△498百万円となりました。
Although the gross profit margin remained at the same level as in the prior-year period, operating profit was negative ¥498 million due to an increase in outsourcing expenses related to the transfer of production, among other factors.

Ordinary profit

−¥467.0mloss widenedvs a year earlier
H1 FY26−¥306.0mH1 FY27−¥467.0m
FY25FY26FY27 · this year-2000200¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼this yearvs same quarter last yearnew forecast-79.0 a quarterlast year
Ordinary profit by quarter
Period¥m
FY25 Q1-161.0
FY25 Q2-106.0
FY25 Q3-104.0
FY25 Q4234.0
FY26 Q1-155.0
FY26 Q2-151.0
FY26 Q3-203.0
FY26 Q4-269.0
FY27 Q1-228.0
FY27 Q2-239.0
last year -778.0
now -625.0
Full-year forecast, ¥mthe first forecast for this year
Forecast from this deck (no earlier forecast on record)
Why

The company recorded ¥53 million in subsidy income, among other items, as non-operating income.

一方、補助金収入53百万円を営業外収益として計上したことなどから、経常利益は△467百万円、中間純利益は△469百万円となりました。
Meanwhile, ordinary profit was negative ¥467 million and interim net income was negative ¥469 million, mainly because ¥53 million in subsidy income was recorded as non-operating income.

Net profit

−¥469.0mloss widenedvs a year earlier
H1 FY26−¥307.0mH1 FY27−¥469.0m
FY25FY26FY27 · this year-2000200¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼this yearvs same quarter last yearnew forecast-79.5 a quarterold forecast-79.5 a quarterlast year
Net profit by quarter
Period¥m
FY25 Q1-161.0
FY25 Q2-107.0
FY25 Q3-105.0
FY25 Q4233.0
FY26 Q1-156.0
FY26 Q2-151.0
FY26 Q3-205.0
FY26 Q4-268.0
FY27 Q1-228.0
FY27 Q2-241.0
last year -780.0
was -628.0
now -628.0
Full-year forecast, ¥m±0.0% vs the old forecast
Old and new forecast from the company's results releases
Why

The interim net loss was ¥469 million, mainly due to ¥53 million in subsidy income, among other factors.

一方、補助金収入53百万円を営業外収益として計上したことなどから、経常利益は△467百万円、中間純利益は△469百万円となりました。
Meanwhile, ordinary profit was negative ¥467 million and interim net income was negative ¥469 million, mainly because ¥53 million in subsidy income was recorded as non-operating income.

Their own numbers

figures this company chose to report, a year ago against now
Estimated number of patients with recurrent meningioma in Japan
4,000 people

The estimated patient population for recurrent meningioma in Japan is approximately 4,000.

Number of patients with recurrent meningioma in China
15,000 people

The patient population in China is estimated at approximately 15,000.

Number of patients with recurrent meningioma in Europe
35,000 people

The patient population in Europe is estimated at approximately 35,000.

Number of cases in the clinical trial for the thoracic malignant tumor basket
30 ExampleFY27 plan

The planned number of cases for the domestic Phase I/II trial is 30.

Commencement of BNCT treatment on Hainan Island
1 Start date

BNCT treatment began in March 2026 at the Hainan Island Medical Special Zone.

The low–high ranges are Komori's estimate, not figures the company gave.

Everything else in the deck

What moved

change vs a year earlier, by the company's own breakdown
Selling, general and administrative expenses
Costs related to the transfer of production+¥191.8m
Personnel-related+¥30.2m
Research and Development Expenses−¥23.7m
Other−¥19.4m
Bar colour is the direction of the amount (red = up, teal = down).

New initiatives

what they said they're starting
  • The company will transfer production to a new manufacturing company and proceed with an application to add a manufacturing site, rebuilding a stable supply system.
  • The company will allocate funds to clinical trials for rare cancers and research and development for deep-seated cancers.
  • The company aims to obtain approval and build a sales structure in mainland China by using real-world clinical data from Hainan Island.
  • The company will establish a business framework for joint development, regulatory filings and sales with its Chinese partner.

What decks usually leave out

COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deck

Progress toward the full-year forecast

share of the year's target already earned, against the same point in past years
Computed
17%of the sales forecast earned
with 50% of the year gone: within the range of the last 4 years (18%–62%)
Operating profit isn't shown: the company forecasts a loss this year, so progress isn't a share of it.
50% of the year gone
FY23
40%
FY24
57%
FY25
18%
FY26
62%
FY27
17%
how much of the year has gonepast-year average at this point (44%)

¥0.2bn earned of the ¥1.0bn forecast.

The rest of the year has to bring in ¥0.9bn, −27 pts off the usual pace.

Progress toward the full-year forecast
Period%
FY2340%
FY2457%
FY2518%
FY2662%
FY2717%

Margins and overheads

where each ¥100 of sales goes
Computed
a year ago-149.0%now-284.6%

Overheads (selling and admin costs): ¥643.6m

Financial targets

the last five years against the target (green band), where one is stated
Computed
Return on equity-22.0%
profit earned on shareholders' money
+5.7 pts on last year
-48%-25%-3%FY22FY23FY24FY25FY26FY27FY22: -46.4%FY23: -26.7%FY24: -29.8%FY25: -5.0%FY26: -27.7%FY27: -22.0% (forecast)-22.0%
Return on equity
Period%
FY22-46.4
FY23-26.7
FY24-29.8
FY25-5.0
FY26-27.7
FY27-22.0
Equity ratio59.2%
how much of the balance sheet is owned outright
+5.1 pts on last year
52%60%67%FY22FY23FY24FY25FY26FY27FY22: 65.3%FY23: 63.3%FY24: 62.0%FY25: 59.2%FY26: 54.1%FY27: 59.2%59.2%
Equity ratio
Period%
FY2265.3
FY2363.3
FY2462.0
FY2559.2
FY2654.1
FY2759.2

Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.

Not mentioned in this deck

15
By businessCapital spendingShare buybackDividendSelf-rating against planForecast assumptionsRisks priced into the forecastMid-term plan targetsA stated financial targetOrders and backlogPrice and volumeStore or site countHeadcountMarket size and shareInvestor Q&A